<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.115300</article-id><article-id pub-id-type="publisher-id">ACM-42271</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210500000_82266196.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  新生儿败血症抗生素治疗的研究进展
  Research Advances in Antibiotic Treatment of Neonatal Sepsis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>芳</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>韦</surname><given-names>红</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>重庆医科大学附属儿童医院新生儿科，重庆；儿童发育疾病研究教育部重点实验室，重庆；国家儿童健康与疾病临床医学研究中心，重庆；儿童发育重大疾病国家国际科技合作基地，重庆；儿科学重庆市重点实验室，重庆</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>05</month><year>2021</year></pub-date><volume>11</volume><issue>05</issue><fpage>2094</fpage><lpage>2099</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  新生儿败血症是新生儿期严重的感染性疾病，是严重威胁新生儿生命的常见疾病之一，发病率及死亡率均较高，早期合理的有效的抗生素治疗是控制感染、降低死亡率、减少并发症的关键，但抗生素的滥用会增加耐药菌产生的风险，合理有效的抗生素管理是必不可少的，本文对目前新生儿败血症的抗生素选择进行了总结。
   Neonatal sepsis is a serious infectious disease in the neonatal period and is one of the common reason that seriously threaten the lives of newborns, with high morbidity and mortality. Early and reasonable effective antibiotic treatment is the key to controlling infection, reducing mortality and minimizing complications, but the misuse of antibiotics increases the risk of drug-resistant bacteria occurrence, reasonable and effective antibiotic management is essential. This article summarises the current antibiotic choices for sepsis.
 
</p></abstract><kwd-group><kwd>新生儿败血症，抗生素，研究进展, Neonatal Sepsis</kwd><kwd> Antibiotics</kwd><kwd> Research Progress</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>新生儿败血症是新生儿期严重的感染性疾病，是严重威胁新生儿生命的常见疾病之一，发病率及死亡率均较高，早期合理的有效的抗生素治疗是控制感染、降低死亡率、减少并发症的关键，但抗生素的滥用会增加耐药菌产生的风险，合理有效的抗生素管理是必不可少的，本文对目前新生儿败血症的抗生素选择进行了总结。</p></sec><sec id="s2"><title>关键词</title><p>新生儿败血症，抗生素，研究进展</p></sec><sec id="s3"><title>Research Advances in Antibiotic Treatment of Neonatal Sepsis</title><p>Fang Wang<sup>1,2,3,4,5</sup>, Hong Wei<sup>1,2,3,4,5*</sup></p><p><sup>1</sup>Department of Neonatology, Children’s Hospital of Chongqing Medical University, Chongqing</p><p><sup>2</sup>Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing</p><p><sup>3</sup>National Clinical Research Center for Child Health and Disorders, Chongqing</p><p><sup>4</sup>China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing</p><p><sup>5</sup>Chongqing Key Laboratory of Pediatrics, Chongqing</p><p><img src="//html.hanspub.org/file/9-1572226x5_hanspub.png" /></p><p>Received: Apr. 11<sup>th</sup>, 2021; accepted: Apr. 25<sup>th</sup>, 2021; published: May 14<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/9-1572226x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Neonatal sepsis is a serious infectious disease in the neonatal period and is one of the common reason that seriously threaten the lives of newborns, with high morbidity and mortality. Early and reasonable effective antibiotic treatment is the key to controlling infection, reducing mortality and minimizing complications, but the misuse of antibiotics increases the risk of drug-resistant bacteria occurrence, reasonable and effective antibiotic management is essential. This article summarises the current antibiotic choices for sepsis.</p><p>Keywords:Neonatal Sepsis, Antibiotics, Research Progress</p><disp-formula id="hanspub.42271-formula31"><graphic xlink:href="//html.hanspub.org/file/9-1572226x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/9-1572226x8_hanspub.png" /> <img src="//html.hanspub.org/file/9-1572226x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>新生儿各个系统发育不成熟，尤其是免疫系统功能不完善，抵御病原菌的能力较弱，极易发生各种感染，新生儿败血症(Neonatal sepsis, NS)是新生儿期严重的感染性疾病，是严重威胁新生儿生命的常见疾病之一，发病率及死亡率均较高，若不能得到及时有效的治疗，会导致病情加重及病程迁延，损伤全身多器官功能，引起重症感染，出现严重的并发症，甚至导致死亡 [<xref ref-type="bibr" rid="hanspub.42271-ref1">1</xref>]。早期合理的有效的抗生素治疗是控制感染、降低死亡率、减少并发症的关键 [<xref ref-type="bibr" rid="hanspub.42271-ref2">2</xref>]。在感染早期没有血培养及药敏“金标准”的指导下，临床医生通常会根据当地微生物易感模式选择经验性广谱抗生素治疗，以及时控制感染、缓解症状 [<xref ref-type="bibr" rid="hanspub.42271-ref3">3</xref>]；然而，滥用广谱抗生素，会增加耐药菌产生的几率。耐药菌的产生导致重症感染难以治愈，增加并发症的发生及死亡率 [<xref ref-type="bibr" rid="hanspub.42271-ref4">4</xref>]。在耐药菌越来越普遍的情况下，如何在有效的控制感染的基础上减少细菌耐药性的产生已成为临床医生面临的巨大挑战 [<xref ref-type="bibr" rid="hanspub.42271-ref5">5</xref>]，合理的抗生素使用策略是减少耐药微生物出现的关键 [<xref ref-type="bibr" rid="hanspub.42271-ref6">6</xref>]。</p></sec><sec id="s6"><title>2. 新生儿败血症的流行病学</title><p>新生儿败血症的发生率约为4.5‰~9.7‰活产新生儿 [<xref ref-type="bibr" rid="hanspub.42271-ref7">7</xref>]。根据发病时间，可分为早发败血症(Early onset sepsis, EOS)及晚发败血症(Late onset sepsis, LOS)，EOS通常指起病时间在生后72小时内的患儿，LOS通常指起病时间大于72小时日龄的患儿 [<xref ref-type="bibr" rid="hanspub.42271-ref8">8</xref>]。EOS在足月儿中的发生率约为1‰~10‰，病死率约为20%，而在早产儿中的发病率约为15%，病死率约为50%。LOS在新生儿中的发生率为0.61%~14.2%，胎龄越小、出生体重越低者发病率越高 [<xref ref-type="bibr" rid="hanspub.42271-ref9">9</xref>]。在发达国家，EOS的病原菌以B族链球菌(group B Streptococcus, GBS) (37.0%~57.4%)和大肠杆菌(Escherichia coli, E. coli)(24.8%~29.0%)为主 [<xref ref-type="bibr" rid="hanspub.42271-ref10">10</xref>]，而在发展中国家，除GBS及E. coli外，克雷伯菌、金黄色葡萄球菌也是EOS的主要病原菌 [<xref ref-type="bibr" rid="hanspub.42271-ref10">10</xref>]。在发达国家，LOS的病原菌以凝固酶阴性葡萄球菌(coagulase negative Staphylococcus, CoNS)为主，而在发展中国家，LOS的病原菌还包括E. coli、肺炎克雷伯菌、金黄色葡萄球菌、肺炎链球菌、假单胞菌、不动杆菌等，且由于抗生素的不合理使用，细菌耐药的问题日益严重 [<xref ref-type="bibr" rid="hanspub.42271-ref11">11</xref>]。</p></sec><sec id="s7"><title>3. 不合理使用抗生素的危害</title><p>有研究证实，长期使用抗生素会增加患儿发生坏死性小肠结肠炎、晚发型败血症、侵袭性真菌感染和死亡的风险 [<xref ref-type="bibr" rid="hanspub.42271-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.42271-ref13">13</xref>]，同时会增加耐药菌产生的几率 [<xref ref-type="bibr" rid="hanspub.42271-ref4">4</xref>]。此外，有研究表明，早期使用抗生素的患儿在1岁以内发生喘息的几率明显高于未使用抗生素的患儿 [<xref ref-type="bibr" rid="hanspub.42271-ref14">14</xref>]。抗生素使用的时间越长，其相关并发症发生的风险也越高，一项对使用抗生素治疗而3天内血培养阴性的极低出生体重儿的研究发现，抗生素的使用时间 ≥ 5天将增加患儿继发坏死性小肠结肠炎(necrotizing enterocolitis, NEC)以及死亡的风险 [<xref ref-type="bibr" rid="hanspub.42271-ref15">15</xref>]。以上研究表明，抗生素的使用可能会增加相关疾病发病的风险，对新生儿的健康可能产生一定的危害。而新生儿败血症是由细菌感染引起的新生儿期严重的感染性疾病，是导致新生儿残疾和死亡的重要原因之一 [<xref ref-type="bibr" rid="hanspub.42271-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.42271-ref16">16</xref>]，如果不能得到积极有效的治疗，则可能产生严重后果。但如何根据患儿的病情、临床表现及实验室检查制定合理的抗生素治疗方案目前尚无统一的标准，且随着耐药菌的增加，有效的抗生素有限，新型抗生素缺乏，以及新生儿特有的药代动力学特点，可供选择的抗生素越来越少。</p></sec><sec id="s8"><title>4. 合理抗生素的选择</title><p>在新生儿抗感染治疗中，抗生素的选择尚缺乏统一的标准 [<xref ref-type="bibr" rid="hanspub.42271-ref17">17</xref>]，但无论是EOS还是LOS，一旦怀疑感染则应该立即使用抗菌药物，及时控制感染，然后根据血培养及药敏试验结果以及其他非特异性炎症指标等检查结果，结合患儿的临床表现，调整抗生素使用方案，决定是否需要继续使用或者更换、停用抗生素；但临床医生一旦排除感染，应该及时停止使用抗菌药物。</p><p>在病原菌尚未明确或者病情危急时，临床医生可以根据患儿的临床表现、感染部位、当地不同感染性疾病的生物易感模式，结合医生的临床经验选择经验性抗生素抗感染治疗。联合用药是目前经验性抗生素抗感染治疗的常用方法之一。根据新生儿败血症菌群的分布情况，EOS联合用药需选用对GBS、E. coli、大多数其他链球菌及李斯特氏菌有效的抗生素，LOS则需选用对E. coli、肺炎克雷伯菌以及金黄色葡萄球菌等有效的抗生素。美国和英国指南推荐使用氨苄青霉素或青霉素联合氨基糖苷类药物作为治疗EOS的一线抗生素 [<xref ref-type="bibr" rid="hanspub.42271-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.42271-ref18">18</xref>]；推荐半合成青霉素联合氨基糖苷类药物作为LOS的经验性抗生素治疗 [<xref ref-type="bibr" rid="hanspub.42271-ref19">19</xref>]，但氨基糖苷类有耳毒性及肾毒性，新生儿使用有导致听力损伤及肾功能损伤的风险 [<xref ref-type="bibr" rid="hanspub.42271-ref20">20</xref>]，故我国相关部门明确规定&lt;6岁者禁用氨基糖苷类抗生素治疗。我国相关指南推荐使用氨苄西林(或者青霉素) + 第三代头孢菌素作为EOS的一线抗感染治疗方案 [<xref ref-type="bibr" rid="hanspub.42271-ref21">21</xref>]，和氨基糖苷类抗生素相比，尽管第三代头孢菌素的抗菌谱更广，但其引起新生儿坏死性小肠结肠炎等严重并发症的发生率及死亡率较高，诱导耐药菌产生的可能性以及继发真菌感染的风险也较高 [<xref ref-type="bibr" rid="hanspub.42271-ref13">13</xref>]。对于LOS，我国指南推荐选用苯唑西林或萘夫西林或万古霉素代替氨苄西林 + 第三代头孢作为经验性抗感染治疗方案；如果怀疑病原菌为铜绿假单胞菌则选用头孢他啶抗感染；对于合并化脓性脑膜炎的患儿，可以考虑联合使用三代头孢抗感染治疗；而对于极低出生体重儿或者胎龄 &lt; 28周的早产儿是否需要预防性使用抗真菌药物目前尚存在争议 [<xref ref-type="bibr" rid="hanspub.42271-ref21">21</xref>]。</p><p>在使用抗生素之前，通常应收集适当的生物学标本送检，完善细菌培养及药敏检查，待病原菌明确后，应根据患儿的临床表现、药敏结果、药物达到感染部位的有效浓度、可能产生的药物不良反应等综合因素来选择合适的抗生素，同时应避免造成抗生素滥用。使用抗生素2~3天后应复查血培养，血培养结果应该转阴，如果仍然阳性需考虑更换抗生素 [<xref ref-type="bibr" rid="hanspub.42271-ref21">21</xref>]。</p><p>新生儿各个器官系统发育不成熟，抗菌药物在新生儿体内的吸收、分布、代谢和排泄均与年长儿及成人不同，而且受到胎龄、日龄及疾病等因素的影响，因此不管病原菌是否明确，都应该结合新生儿的药代动力学特点选择合适的药物。</p></sec><sec id="s9"><title>5. 抗生素治疗的疗程</title><p>对于血培养阳性的患儿，应给予足疗程足剂量的有效的抗生素治疗。对于血培养证实为败血症，而没有合并颅内感染、细菌性脑膜炎的患儿治疗时间通常为为10~14天；对于胎龄 ≥ 32周、体重 ≥ 1500 g，经有效抗生素治疗后5天内临床症状消失的患儿，如果实验室结果正常，血培养结果阴性，且患儿临床表现好，在保证适当随访的情况下，可缩短抗生素的疗程至7~10天；对于合并有细菌性脑膜炎的患儿，病原菌为GBS建议疗程14~21天，李斯特菌建议疗程 ≥ 21天，革兰阴性菌疗程则至少21天 [<xref ref-type="bibr" rid="hanspub.42271-ref22">22</xref>]。对于病原菌为金黄色葡萄球菌而无合并症的败血症新生儿，建议抗生素疗程为14天，而对于有合并症者，则需要更长的抗生素治疗时间 [<xref ref-type="bibr" rid="hanspub.42271-ref23">23</xref>]。</p><p>对于疑似败血症的血培养阴性的患儿，抗生素的疗程目前难以确定 [<xref ref-type="bibr" rid="hanspub.42271-ref22">22</xref>]。通常认为，如果在36~48 h血培养阴性，且患儿没有败血症的临床证据，则应该及时停用抗生素 [<xref ref-type="bibr" rid="hanspub.42271-ref19">19</xref>]，停用抗生素后，需要密切观察患儿的病情变化，随访其炎症指标，必要时需再次予以抗生素抗感染治疗。</p><p>有研究表明，连续两次未成熟中性粒细胞数/总中性粒细胞数值(immature to total neutrophil ratio, I/T)均正常，且24小时内血培养阴性者，抗生素使用24小时后停用较安全，其阴性预测值为100% [<xref ref-type="bibr" rid="hanspub.42271-ref24">24</xref>]。降钙素原(PCT)在新生儿重症感染中也有较好的阴性预测值，连续2次PCT值正常可知道抗生素停用，可能对减少新生儿败血症抗生素疗程有指导意义 [<xref ref-type="bibr" rid="hanspub.42271-ref25">25</xref>]。有研究提出对于无症状的疑诊新生儿早发败血症的足月及近足月者，可进行连续体格检查指导抗生素治疗，从而减少实验室检查及不必要的抗生素治疗 [<xref ref-type="bibr" rid="hanspub.42271-ref26">26</xref>]。此外，C反应蛋白(CRP)值也有助于排除感染，指导抗生素的使用，连续两次CRP阴性也可知道抗生素的停用 [<xref ref-type="bibr" rid="hanspub.42271-ref27">27</xref>]。在停用抗生素后仍需要严密观察患儿病情，必要时可再次进行血培养及其他实验室检查，根据检查结果使用合理的抗生素治疗。</p></sec><sec id="s10"><title>6. 总结</title><p>新生儿败血症是新生儿期发病率较高的严重感染性疾病，尽管抗生素的使用会增加患儿继发坏死性小肠结肠炎、晚发型败血症、侵袭性真菌感染和死亡的风险，但及时有效的抗生素治疗是控制感染、减少并发症、改善预后的关键。在没有血培养结果的指导下，临床医生应该根据患儿的临床表现、当地微生物易感模式选择经验性抗生素治疗，病原菌明确时，应综合分析患儿的临床表现及实验室检查，根据病情调整抗生素用药。对于细菌培养阴性且临床表现稳点的患儿，应及时停止抗生素使用。目前国内外抗生素耐药的问题日趋严重，如何在有效的控制感染的基础上减少耐药菌的产生是临床医生面临的巨大挑战。有效的抗生素管理是减少耐药菌产生的重要措施。</p></sec><sec id="s11"><title>文章引用</title><p>王 芳,韦 红. 新生儿败血症抗生素治疗的研究进展Research Advances in Antibiotic Treatment of Neonatal Sepsis[J]. 临床医学进展, 2021, 11(05): 2094-2099. https://doi.org/10.12677/ACM.2021.115300</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42271-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">李志强, 王冠达, 黄艳. 延时与间断输注美罗培南治疗重症感染患者的系统评价[J]. 中国医院药学杂志, 2017, 37(2): 155-160.</mixed-citation></ref><ref id="hanspub.42271-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Rhodes, A., Evans, L.E., Alhazzani, W., Levy, M.M., Antonelli, M., Ferrer, R., et al. (2017) Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med, 43, 304-377.  
&lt;br&gt;https://doi.org/10.1007/s00134-017-4683-6</mixed-citation></ref><ref id="hanspub.42271-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ain Ibrahim, N., Makmor Bakry, M., Mohd Tahir, N.A., Mohd Zaini, N.R. and Mohamed Shah, N. (2020) A Prospective Cohort Study of Factors Associated with Empiric Antibiotic De-Escalation in Neonates Suspected with Early Onset Sepsis (EOS). Pediatric Drugs, 22, 321-330. &lt;br&gt;https://doi.org/10.1007/s40272-020-00388-1</mixed-citation></ref><ref id="hanspub.42271-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">闫桦, 王晶, 齐赛卿, 张海峰. 美罗培南在新生儿重症感染治疗中的应用价值及安全性[J]. 儿科药学杂志, 2017, 23(2): 16-18.</mixed-citation></ref><ref id="hanspub.42271-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Luque-Sastre, L., Arroyo, C., Fox, E.M., McMahon, B.J., Bai, L., Li, F. and Fanning, S. (2018) Antimicrobial Resistance in Listeria Species. In: Schwarz, S., Cavaco, L. and Shen, J., Eds., Antimicrobial Resistance in Bacteria from Livestock and Companion Animals, ASM Press, Washington DC, 237-259.  
&lt;br&gt;https://doi.org/10.1128/microbiolspec.ARBA-0031-2017</mixed-citation></ref><ref id="hanspub.42271-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Schechner, V., Temkin, E., Harbarth, S., Carmeli, Y. and Schwaber, M.J. (2013) Epidemiological Interpretation of Studies Examining the Effect of Antibiotic Usage on Resistance. Clinical Microbiology Reviews, 26, 289-307.  
&lt;br&gt;https://doi.org/10.1128/CMR.00001-13</mixed-citation></ref><ref id="hanspub.42271-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Liu, L., Oza, S., Hogan, D., Chu, Y., Perin, J., Zhu, J., Lawn, J.E., Cousens, S., Mathers, C. and Black, R.E. (2016) Global, Regional, and National Causes of Under-5 Mortality in 2000-15: An Updated Systematic Analysis with Implications for the Sustainable Development Goals. The Lancet, 388, 3027-3035.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(16)31593-8</mixed-citation></ref><ref id="hanspub.42271-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Polin, R.A. and the Committee on Fetus and Newborn (2012) Management of Neonates with Suspected or Proven Early-Onset Bacterial Sepsis. Pediatrics, 129, 1006-1015. &lt;br&gt;https://doi.org/10.1542/peds.2012-0541</mixed-citation></ref><ref id="hanspub.42271-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Dong, Y. and Speer, C.P. (2015) Late-Onset Neonatal Sepsis: Recent Developments. Archives of Disease in Childhood-Fetal and Neonatal Edition, 100, F257-F263. &lt;br&gt;https://doi.org/10.1136/archdischild-2014-306213</mixed-citation></ref><ref id="hanspub.42271-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Fjalstad, J.W., Stensvold, H.J., Bergseng, H., Simonsen, G.S., Salvesen, B., Ronnestad, A.E. and Klingenberg, C. (2016) Early-Onset Sepsis and Antibiotic Exposure in Term Infants: A Nationwide Population-Based Study in Norway. The Pediatric Infectious Disease Journal, 35, 1-6. &lt;br&gt;https://doi.org/10.1097/INF.0000000000000906</mixed-citation></ref><ref id="hanspub.42271-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Hamer, D.H., Darmstadt, G.L., Carlin, J.B., Zaidi, A.K., Yeboah-Antwi, K., Saha, S.K., et al. (2015) Etiology of Bacteremia in Young Infants in Six Countries. The Pediatric Infectious Disease Journal, 34, e1-e8.  
&lt;br&gt;https://doi.org/10.1097/INF.0000000000000549</mixed-citation></ref><ref id="hanspub.42271-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J.H., Hornik, C.P, Benjamin Jr., D.K., Herring, A.H., Clark, R.H., Cohen-Wolkowiez, M. and Smith, P.B. (2013) Risk Factors for Invasive Candidiasis in Infants &gt;1500g Birth Weight. The Pediatric Infectious Disease Journal, 32, 222-226. &lt;br&gt;https://doi.org/10.1097/INF.0b013e3182769603</mixed-citation></ref><ref id="hanspub.42271-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kuppala, V.S., Meinzen-Derr, J., Morrow, A.L. and Schibler, K.R. (2011) Prolonged Initial Empirical Antibiotic Treatment Is Associated with Adverse Outcomes in Premature Infants. The Journal of Pediatrics, 159, 720-725.  
&lt;br&gt;https://doi.org/10.1016/j.jpeds.2011.05.033</mixed-citation></ref><ref id="hanspub.42271-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Oosterloo, B.C., van Elburg, R.M., Rutten, N.B., Bunkers, C.M., Crijns, C.E., Meijssen, C.B., Oudshoorn, J.H., Rijkers, G.T., van der Ent, C.K. and Vlieger, A.M. (2018) Wheezing and Infantile Colic Are Associated with Neonatal Antibiotic Treatment. Pediatric Allergy and Immunology, 29, 151-158. &lt;br&gt;https://doi.org/10.1111/pai.12857</mixed-citation></ref><ref id="hanspub.42271-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Cotten, C.M., Taylor, S., Stoll, B., Goldberg, R.N., Hansen, N.I., Sanchez, P.J., Ambalavanan, N., Benjamin, D.K., Jr. and Network, N.N.R. (2009) Prolonged Duration of Initial Empirical Antibiotic Treatment Is Associated with Increased Rates of Necrotizing Enterocolitis and Death for Extremely Low Birth Weight Infants. Pediatrics, 123, 58-66.  
&lt;br&gt;https://doi.org/10.1542/peds.2007-3423</mixed-citation></ref><ref id="hanspub.42271-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Folgori, L., Ellis, S.J., Bielicki, J.A., Heath, P.T., Sharland, M. and Balasegaram, M. (2017) Tackling Antimicrobial Resistance in Neonatal Sepsis. The Lancet Global Health, 5, e1066-e1068.  
&lt;br&gt;https://doi.org/10.1016/S2214-109X(17)30362-5</mixed-citation></ref><ref id="hanspub.42271-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Leroux, S., Zhao, W., Betremieux, P., Pladys, P., Saliba, E. and Jacqz-Aigrain, E. on Behalf of the French Society of Neonatology (2015) Therapeutic Guidelines for Prescribing Antibiotics in Neonates Should Be Evidence-Based: A French National Survey. Archives of Disease in Childhood, 100, 394-398.  
&lt;br&gt;https://doi.org/10.1136/archdischild-2014-306873</mixed-citation></ref><ref id="hanspub.42271-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Caffrey Osvald, E. and Prentice, P. (2014) NICE Clinical Guideline: Antibiotics for the Prevention and Treatment of Early-Onset Neonatal Infection. Archives of Disease in Childhood-Education and Practice, 99, 98-100.  
&lt;br&gt;https://doi.org/10.1136/archdischild-2013-304629</mixed-citation></ref><ref id="hanspub.42271-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Cantey, J.B. (2016) Optimizing the Use of Antibacterial Agents in the Neonatal Period. Pediatric Drugs, 18, 109-122.  
&lt;br&gt;https://doi.org/10.1007/s40272-015-0161-1</mixed-citation></ref><ref id="hanspub.42271-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Stoll, B.J., Hansen, N.I., Adams-Chapman, I., Fanaroff, A.A., Hintz, S.R., Vohr, B. and Higgins, R.D. (2004) Neurodevelopmental and Growth Impairment among Extremely Low-Birth-Weight Infants with Neonatal Infection. JAMA, 292, 2357-2365. &lt;br&gt;https://doi.org/10.1001/jama.292.19.2357</mixed-citation></ref><ref id="hanspub.42271-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会儿科学分会新生儿学组, 中国医师协会新生儿科医师分会感染专业委员会. 新生儿败血症诊断及治疗专家共识(2019年版) [J]. 中华儿科杂志, 2019, 57(4): 252-257.</mixed-citation></ref><ref id="hanspub.42271-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Sivanandan, S., Soraisham, A.S. and Swarnam, K. (2011) Choice and Duration of Antimicrobial Therapy for Neonatal Sepsis and Meningitis. International Journal of Pediatrics, 2011, Article ID: 712150.  
&lt;br&gt;https://doi.org/10.1155/2011/712150</mixed-citation></ref><ref id="hanspub.42271-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kempley, S., Kapellou, O., McWilliams, A., Banerjee, J., McCorqodale, A. and Millar, M. (2015) Antibiotic Treatment Duration and Prevention of Complications in Neonatal Staphylococcus aureus Bacteraemia. Journal of Hospital Infection, 91, 129-135. &lt;br&gt;https://doi.org/10.1016/j.jhin.2015.07.002</mixed-citation></ref><ref id="hanspub.42271-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Murphy, K. and Weiner, J. (2012) Use of Leukocyte Counts in Evaluation of Early-Onset Neonatal Sepsis. The Pediatric Infectious Disease Journal, 31, 16-19. &lt;br&gt;https://doi.org/10.1097/INF.0b013e31822ffc17</mixed-citation></ref><ref id="hanspub.42271-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Stocker, M., van Herk, W., el Helou, S., Dutta, S., Fontana, M.S., Schuerman, F.A.B.A., van den Tooren-de Groot, R.K., Wieringa, J.W., Janota, J., van der Meer-Kappelle, L.H., et al. (2017) Procalcitonin-Guided Decision Making for Duration of Antibiotic Therapy in Neonates with Suspected Early-Onset Sepsis: A Multicentre, Randomised Controlled Trial (NeoPIns). The Lancet, 390, 871-881. &lt;br&gt;https://doi.org/10.1016/S0140-6736(17)31444-7</mixed-citation></ref><ref id="hanspub.42271-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Berardi, A., Tzialla, C., Travan, L., Bua, J., Santori, D., Azzalli, M., Spada, C. and Lucaccioni, L. on Behalf of the GBS Prevention Working Group of Emilia-Romagna (2018) Secondary Prevention of Early-Onset Sepsis: A Less Invasive Italian Approach for Managing Neonates at Risk. Italian Journal of Pediatrics, 44, Article No. 73.  
&lt;br&gt;https://doi.org/10.1186/s13052-018-0515-8</mixed-citation></ref><ref id="hanspub.42271-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Benitz, W.E., Wynn, J.L. and Polin, R.A. (2015) Reappraisal of Guidelines for Management of Neonates with Suspected Early-Onset Sepsis. Journal of Pediatrics, 166, 1070-1074. &lt;br&gt;https://doi.org/10.1016/j.jpeds.2014.12.023</mixed-citation></ref></ref-list></back></article>